Bausch Health Files 8-K Report
Ticker: BHC · Form: 8-K · Filed: Nov 24, 2025 · CIK: 885590
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: BHC
TL;DR
Bausch Health filed an 8-K, likely with updates. Keep an eye out.
AI Summary
On November 24, 2025, Bausch Health Companies Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and "Financial Statements and Exhibits." No specific transactions or financial details were disclosed in the provided excerpt.
Why It Matters
This filing signals that Bausch Health is making a regulatory disclosure, which could pertain to significant corporate events or financial updates, requiring investor attention.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of negative events or significant financial changes.
Key Players & Entities
- Bausch Health Companies Inc. (company) — Registrant
- November 24, 2025 (date) — Date of report
- Valeant Pharmaceuticals International, Inc. (company) — Former company name
- BIOVAIL Corp (company) — Former company name
FAQ
What specific event triggered this 8-K filing?
The provided excerpt does not specify the exact event, only that it falls under 'Other Events' and 'Financial Statements and Exhibits'.
When was this report filed?
The report was filed on November 24, 2025.
What is the primary business of Bausch Health Companies Inc.?
Bausch Health Companies Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What were Bausch Health's former names?
Bausch Health Companies Inc. was formerly known as Valeant Pharmaceuticals International, Inc., BIOVAIL Corp, and BIOVAIL CORP INTERNATIONAL.
Where is Bausch Health Companies Inc. headquartered?
The company's business address is located at 2150 St. Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8.
Filing Stats: 1,500 words · 6 min read · ~5 pages · Grade level 13.7 · Accepted 2025-11-24 07:10:30
Key Financial Figures
- $1.6 billion — isting Senior Secured Notes") for up to $1.6 billion aggregate principal amount (the "Maximu
- $4.4 billion — le series with the Issuer's outstanding $4.4 billion principal amount of 10.00% Senior Secur
- $1,545 million — ating Holders"), who hold approximately $1,545 million aggregate principal amount of existing
Filing Documents
- d72478d8k.htm (8-K) — 32KB
- d72478dex991.htm (EX-99.1) — 25KB
- 0001193125-25-291998.txt ( ) — 179KB
- bhc-20251124.xsd (EX-101.SCH) — 2KB
- bhc-20251124_lab.xml (EX-101.LAB) — 18KB
- bhc-20251124_pre.xml (EX-101.PRE) — 11KB
- d72478d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Number Description 99.1* Press Release of Bausch Health Companies Inc., dated November 24, 2025, relating to the commencement of exchange offers 104* Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 24, 2025 BAUSCH HEALTH COMPANIES INC. By: /s/ Jean-Jacques Charhon Jean-Jacques Charhon Executive Vice President, Chief Financial Officer (Principal Financial Officer)